Actively Recruiting
Phase II Trial of Adding Adalimumab to Standard Tuberculosis Meningitis Treatment in HIV-1 Infected Adults
Led by ANRS, Emerging Infectious Diseases · Updated on 2025-12-15
130
Participants Needed
3
Research Sites
26 weeks
Total Duration
AI-Summary
What This Trial Is About
This clinical trial studies adults with HIV-1 infection who have tuberculosis meningitis TBM. It is a phase II, randomized, open-label trial conducted in Brazil, Mozambique, and Zambia. The trial aims to evaluate whether adding the drug adalimumab, a tumor necrosis factor inhibitor, to the usual treatment of anti-tuberculosis drugs and high-dose steroids affects mortality at 3 months and is safe for these patients. Participants will start standard TBM treatment including anti-tuberculosis drugs for about 9 months and high-dose dexamethasone steroids for up to 4 weeks. Patients are randomly assigned within the first 3 days of treatment to either standard care alone or standard care plus adalimumab injections. Those in the adalimumab group receive 40 mg injections every two weeks for 10 weeks, totaling six injections. Antiretroviral therapy ART for HIV will begin after 4 weeks of TB treatment if the patient improves clinically, but no later than 8 weeks. During the study, participants will be monitored closely with various assessments including mortality rates at 3, 9, and 12 months, infections, adverse events, disability scores, neurological evaluations, and laboratory tests such as cerebrospinal fluid analysis and blood biomarkers. Safety will be assessed with an interim analysis after 20 patients receive adalimumab and are followed for 3 months. The total participation may last up to 12 months with ongoing evaluations of health and response to treatments.
CONDITIONS
Brief Title
Tnf Inhibitors to Reduce Mortality in HIV-1 Infected PAtients With Tuberculosis meNIngitis
Research Team
V
Vanessa MACHAULT, PhD
O
Olivier MARCY, MD PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here